Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.

Grade Last Price % Change Price Change
F 35.3 2.56% 0.88
FDMT closed down 8.68 percent on Monday, April 12, 2021, on 1.25 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical FDMT trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 2.56%
New 52 Week Low Weakness 2.56%
Wide Bands Range Expansion 2.56%
Lower Bollinger Band Touch Weakness 2.56%
Multiple of Ten Bearish Other -6.34%
Wide Bands Range Expansion -6.34%
NR7 Range Contraction -13.01%
Multiple of Ten Bullish Other -13.01%
Wide Bands Range Expansion -13.01%
Multiple of Ten Bullish Other -12.25%
Older End-of-Day Signals for FDMT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 2 hours ago
Up 3% about 2 hours ago
60 Minute Opening Range Breakdown about 4 hours ago
Up 2% about 6 hours ago
Up 1% about 6 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


4D Molecular Therapeutics, Inc. Description

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Antibodies Emerging Technologies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Of The Human Retina Gene Therapy Products

Is FDMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 55.11
52 Week Low 33.97
Average Volume 170,104
200-Day Moving Average 0.00
50-Day Moving Average 43.84
20-Day Moving Average 41.37
10-Day Moving Average 39.45
Average True Range 3.91
ADX 11.79
+DI 16.64
-DI 25.68
Chandelier Exit (Long, 3 ATRs ) 41.31
Chandelier Exit (Short, 3 ATRs ) 45.71
Upper Bollinger Band 48.67
Lower Bollinger Band 34.07
Percent B (%b) 0.02
BandWidth 35.28
MACD Line -1.75
MACD Signal Line -1.29
MACD Histogram -0.4569
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.81
Resistance 3 (R3) 40.25 38.91 38.91
Resistance 2 (R2) 38.91 37.54 38.68 38.61
Resistance 1 (R1) 36.66 36.69 35.99 36.22 38.31
Pivot Point 35.32 35.32 34.98 35.09 35.32
Support 1 (S1) 33.07 33.95 32.40 32.63 30.53
Support 2 (S2) 31.73 33.10 31.50 30.23
Support 3 (S3) 29.48 31.73 29.93
Support 4 (S4) 29.04